Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation CADTH. Aripiprazole (Abilify — Bristol-Myers Squibb Canada) new indication: major depressive disorder. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). CDEC Final Recommendation; SR0354. 2014 Authors' conclusions The Canadian Drug Expert Committee (CDEC) recommends that sofosbuvir (SOF) be listed for the treatment of chronic hepatitis C (CHC) virus infection in adult patients with compensated liver disease, including cirrhosis, if criteria and conditions are met. Indexing Status Subject indexing assigned by CRD MeSH Antidepressive Agents; Antipsychotic Agentss; Depressive Disorder, Major; Piperazines; Quinolones Language Published English Country of organisation Canada English summary An English language summary is available. Address for correspondence Canadian Agency for Drugs and Technologies in Health (CADTH), 865 Carling Avenue, Suite 600, Ottawa, Ontario Canada, K1S 5S8 Email: requests@cadth.ca AccessionNumber 32015000165 Date abstract record published 04/03/2015 |